MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading 14.8% Higher – What’s Next?

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA)’s share price rose 14.8% during mid-day trading on Monday . The stock traded as high as $1.79 and last traded at $1.78. Approximately 127,633 shares changed hands during trading, a decline of 45% from the average daily volume of 231,425 shares. The stock had previously closed at $1.55.

MAIA Biotechnology Price Performance

The stock has a market cap of $46.56 million, a price-to-earnings ratio of -1.29 and a beta of 0.20. The business’s 50 day moving average is $1.67 and its 200 day moving average is $2.16.

Hedge Funds Weigh In On MAIA Biotechnology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new stake in shares of MAIA Biotechnology in the 3rd quarter valued at about $31,000. Jane Street Group LLC acquired a new stake in shares of MAIA Biotechnology in the fourth quarter valued at approximately $77,000. Finally, Geode Capital Management LLC grew its position in shares of MAIA Biotechnology by 22.9% during the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock worth $541,000 after acquiring an additional 35,821 shares during the last quarter. 5.65% of the stock is owned by institutional investors and hedge funds.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.